1	Suppression	Suppression	B-NP	NN	O	7	NMOD	18	Suppression
2	of	of	B-PP	IN	O	1	NMOD	-1
3	lung	lung	B-NP	NN	O	5	NMOD	-1
4	tumor	tumor	I-NP	NN	O	5	NMOD	-1
5	growth	growth	I-NP	NN	O	2	PMOD	4	growth
6	and	and	I-NP	CC	O	7	NMOD	-1
7	metastasis	metastasis	I-NP	NN	O	0	ROOT	14	metastasis
8	in	in	B-PP	IN	O	7	NMOD	-1
9	mice	mouse	B-NP	NNS	O	8	PMOD	-1
10	by	by	B-PP	IN	O	7	NMOD	-1
11	adeno-associated	adeno-associated	B-NP	JJ	O	13	NMOD	-1
12	virus-mediated	virus-mediated	I-NP	JJ	O	13	NMOD	17	mediated
13	expression	expression	I-NP	NN	O	10	PMOD	9	expression
14	of	of	B-PP	IN	O	13	NMOD	-1
15	vasostatin	vasostatin	B-NP	NN	B-protein	14	PMOD	-1
16	.	.	O	.	O	7	P	-1

1	PURPOSE	PURPOSE	B-NP	NN	O	4	NMOD	-1
2	:	:	O	:	O	1	P	-1
3	Angiogenesis	Angiogenesis	B-NP	NN	O	4	NMOD	3	Angiogenesis
4	inhibitors	inhibitor	I-NP	NNS	O	5	SUB	-1
5	have	have	B-VP	VBP	O	0	ROOT	-1
6	strong	strong	B-NP	JJ	O	7	AMOD	-1
7	therapeutic	therapeutic	I-NP	JJ	O	8	NMOD	-1
8	potential	potential	I-NP	NN	O	5	OBJ	0
9	as	as	B-PP	IN	O	5	VMOD	-1
10	antitumor	antitumor	B-NP	JJ	O	11	NMOD	-1
11	agents	agent	I-NP	NNS	O	9	PMOD	-1
12	in	in	B-PP	IN	O	5	VMOD	-1
13	suppressing	suppress	B-VP	VBG	O	12	PMOD	18	suppressing
14	tumor	tumor	B-NP	NN	O	15	NMOD	-1
15	growth	growth	I-NP	NN	O	18	NMOD	4	growth
16	and	and	O	CC	O	18	NMOD	-1
17	metastatic	metastatic	B-NP	JJ	O	18	NMOD	0
18	progression	progression	I-NP	NN	O	13	OBJ	0
19	.	.	O	.	O	5	P	-1

1	Vasostatin	Vasostatin	B-NP	NN	B-protein	5	NMOD	-1
2	,	,	O	,	O	5	P	-1
3	the	the	B-NP	DT	O	5	NMOD	-1
4	N-terminal	N-terminal	I-NP	JJ	B-protein	5	NMOD	-1
5	domain	domain	I-NP	NN	I-protein	9	SUB	-1
6	of	of	B-PP	IN	O	5	NMOD	-1
7	calreticulin	calreticulin	B-NP	NN	B-protein	6	PMOD	-1
8	,	,	O	,	O	5	P	-1
9	is	be	B-VP	VBZ	O	0	ROOT	-1
10	a	a	B-NP	DT	O	13	NMOD	-1
11	potent	potent	I-NP	JJ	O	13	NMOD	-1
12	angiogenesis	angiogenesis	I-NP	NN	O	13	NMOD	3	angiogenesis
13	inhibitor	inhibitor	I-NP	NN	O	9	PRD	0
14	.	.	O	.	O	9	P	-1

1	In	In	B-PP	IN	O	6	VMOD	-1
2	this	this	B-NP	DT	O	3	NMOD	-1
3	study	study	I-NP	NN	O	1	PMOD	-1
4	,	,	O	,	O	6	P	-1
5	we	we	B-NP	PRP	O	6	SUB	-1
6	determined	determine	B-VP	VBD	O	0	ROOT	-1
7	the	the	B-NP	DT	O	8	NMOD	-1
8	effectiveness	effectiveness	I-NP	NN	O	6	OBJ	16	effectiveness
9	of	of	B-PP	IN	O	8	NMOD	-1
10	vasostatin	vasostatin	B-NP	NN	O	9	PMOD	-1
11	delivered	deliver	B-VP	VBN	O	10	NMOD	19	delivered
12	by	by	B-PP	IN	O	11	VMOD	-1
13	recombinant	recombinant	B-NP	JJ	B-protein	16	NMOD	-1
14	pseudotype	pseudotype	I-NP	NN	I-protein	16	NMOD	-1
15	adeno-associated	adeno-associated	I-NP	JJ	I-protein	16	NMOD	-1
16	virus	virus	I-NP	NN	I-protein	12	PMOD	-1
17	2/5	2/5	I-NP	CD	I-protein	16	NMOD	-1
18	(	(	O	(	O	20	DEP	-1
19	rAAV2/5-VAS	rAAV2/5-VAS	B-NP	NN	O	20	DEP	-1
20	)	)	O	)	O	16	NMOD	-1
21	as	as	B-PP	IN	O	6	VMOD	-1
22	a	a	B-NP	DT	O	25	NMOD	-1
23	gene	gene	I-NP	NN	O	25	NMOD	-1
24	therapy	therapy	I-NP	NN	O	25	NMOD	0
25	approach	approach	I-NP	NN	O	21	PMOD	-1
26	for	for	B-PP	IN	O	25	NMOD	-1
27	lung	lung	B-NP	NN	O	29	NMOD	-1
28	cancer	cancer	I-NP	NN	O	29	NMOD	-1
29	treatment	treatment	I-NP	NN	O	26	PMOD	0
30	.	.	O	.	O	6	P	-1

1	EXPERIMENTAL	EXPERIMENTAL	B-NP	JJ	O	2	NMOD	-1
2	DESIGN	DESIGN	I-NP	NN	O	30	NMOD	-1
3	:	:	O	:	O	2	P	-1
4	We	We	B-NP	PRP	O	5	SUB	-1
5	used	use	B-VP	VBD	O	6	NMOD	0
6	rAAV2/5	rAAV2/5	B-NP	NN	O	30	NMOD	-1
7	to	to	B-VP	TO	O	8	VMOD	-1
8	deliver	deliver	I-VP	VB	O	6	SBAR	19	deliver
9	vasostatin	vasostatin	B-NP	NN	O	8	OBJ	-1
10	intratumorally	intratumorally	B-ADVP	RB	O	8	VMOD	-1
11	or	or	I-ADVP	CC	O	10	AMOD	-1
12	systemically	systemically	I-ADVP	RB	O	10	AMOD	-1
13	in	in	B-PP	IN	O	10	DEP	-1
14	different	different	B-NP	JJ	O	18	NMOD	-1
15	mouse	mouse	I-NP	NN	O	18	NMOD	-1
16	lung	lung	I-NP	NN	O	18	NMOD	-1
17	tumor	tumor	I-NP	NN	O	18	NMOD	-1
18	models	model	I-NP	NNS	O	13	PMOD	-1
19	--	--	O	:	O	30	P	-1
20	subcutaneous	subcutaneous	B-NP	JJ	O	30	NMOD	-1
21	,	,	I-NP	,	O	30	P	-1
22	orthotopic	orthotopic	I-NP	JJ	O	23	NMOD	-1
23	xenograft	xenograft	I-NP	NN	O	30	NMOD	-1
24	,	,	O	,	O	30	P	-1
25	and	and	O	CC	O	30	NMOD	-1
26	spontaneous	spontaneous	B-NP	JJ	O	30	NMOD	-1
27	metastasis	metastasis	I-NP	NN	O	30	NMOD	0
28	lung	lung	I-NP	NN	O	30	NMOD	-1
29	tumor	tumor	I-NP	NN	O	30	NMOD	-1
30	models	model	I-NP	NNS	O	0	ROOT	-1
31	.	.	O	.	O	30	P	-1

1	The	The	B-NP	DT	O	3	NMOD	-1
2	therapeutic	therapeutic	I-NP	JJ	O	3	NMOD	-1
3	efficacy	efficacy	I-NP	NN	O	6	SUB	0
4	of	of	B-PP	IN	O	3	NMOD	-1
5	rAAV2/5-VAS	rAAV2/5-VAS	B-NP	NN	O	4	PMOD	-1
6	was	be	B-VP	VBD	O	0	ROOT	-1
7	determined	determine	I-VP	VBN	O	6	VC	-1
8	by	by	B-PP	IN	O	7	VMOD	-1
9	monitoring	monitor	B-VP	VBG	O	8	PMOD	-1
10	tumor	tumor	B-NP	NN	O	11	NMOD	-1
11	volume	volume	I-NP	NN	O	17	NMOD	-1
12	,	,	O	,	O	17	P	-1
13	survival	survival	B-NP	NN	O	14	NMOD	0
14	rate	rate	I-NP	NN	O	17	NMOD	-1
15	,	,	O	,	O	17	P	-1
16	and	and	O	CC	O	17	NMOD	-1
17	degree	degree	B-NP	NN	O	9	OBJ	-1
18	of	of	B-PP	IN	O	17	NMOD	-1
19	neovascularization	neovascularization	B-NP	NN	O	18	PMOD	3	neovascularization
20	after	after	B-PP	IN	O	9	VMOD	-1
21	treatment	treatment	B-NP	NN	O	20	PMOD	0
22	in	in	B-PP	IN	O	21	NMOD	-1
23	these	these	B-NP	DT	O	24	NMOD	-1
24	models	model	I-NP	NNS	O	22	PMOD	-1
25	.	.	O	.	O	6	P	-1

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	-1
3	Mice	Mouse	B-NP	NNS	O	14	SUB	-1
4	bearing	bear	B-VP	VBG	O	3	NMOD	-1
5	subcutaneous	subcutaneous	B-NP	JJ	O	6	NMOD	-1
6	tumor	tumor	I-NP	NN	O	4	OBJ	-1
7	of	of	B-PP	IN	O	6	NMOD	-1
8	rAAV2/5-VAS	rAAV2/5-VAS	B-NP	NN	B-cell_line	13	NMOD	-1
9	pretreated	pretreate	B-VP	VBN	I-cell_line	13	NMOD	19	pretreated
10	Lewis	Lewis	B-NP	NNP	I-cell_line	13	NMOD	-1
11	lung	lung	I-NP	NN	I-cell_line	13	NMOD	-1
12	carcinoma	carcinoma	I-NP	NN	I-cell_line	13	NMOD	-1
13	cells	cell	I-NP	NNS	I-cell_line	7	PMOD	-1
14	showed	show	B-VP	VBD	O	1	NMOD	-1
15	>	>	B-NP	SYM	O	17	AMOD	-1
16	50	50	B-NP	CD	O	17	AMOD	-1
17	%	%	I-NP	NN	O	18	NMOD	-1
18	reduction	reduction	I-NP	NN	O	14	OBJ	18	reduction
19	in	in	B-PP	IN	O	18	NMOD	-1
20	primary	primary	B-NP	JJ	O	22	NMOD	-1
21	tumor	tumor	I-NP	NN	O	22	NMOD	-1
22	volume	volume	I-NP	NN	O	19	PMOD	-1
23	and	and	O	CC	O	14	VMOD	-1
24	reduced	reduce	B-VP	VBD	O	14	VMOD	18	reduced
25	spontaneous	spontaneous	B-NP	JJ	B-protein	27	NMOD	-1
26	pulmonary	pulmonary	I-NP	JJ	I-protein	27	NMOD	-1
27	metastases	metastasis	I-NP	NNS	I-protein	24	OBJ	14	metastases
28	.	.	O	.	O	1	P	-1

1	The	The	B-NP	DT	O	3	NMOD	-1
2	tumor-suppressive	tumor-suppressive	I-NP	JJ	O	3	NMOD	-1
3	action	action	I-NP	NN	O	13	SUB	0
4	of	of	B-PP	IN	O	3	NMOD	-1
5	rAAV2/5-VAS	rAAV2/5-VAS	B-NP	NN	B-protein	4	PMOD	-1
6	in	in	B-PP	IN	O	3	NMOD	-1
7	subcutaneous	subcutaneous	B-NP	JJ	O	12	NMOD	-1
8	human	human	I-NP	JJ	O	12	NMOD	-1
9	lung	lung	I-NP	NN	O	12	NMOD	-1
10	tumor	tumor	I-NP	NN	O	12	NMOD	-1
11	A549	A549	I-NP	NN	O	12	NMOD	-1
12	xenograft	xenograft	I-NP	NN	O	6	PMOD	-1
13	correlated	correlate	B-VP	VBD	O	0	ROOT	-1
14	with	with	B-PP	IN	O	13	VMOD	-1
15	a	a	B-NP	DT	O	17	NMOD	-1
16	reduced	reduce	I-NP	VBN	O	17	NMOD	18	reduced
17	number	number	I-NP	NN	O	14	PMOD	-1
18	of	of	B-PP	IN	O	17	NMOD	-1
19	capillary	capillary	B-NP	JJ	O	20	NMOD	-1
20	vessels	vessel	I-NP	NNS	O	18	PMOD	-1
21	in	in	B-PP	IN	O	20	NMOD	-1
22	tumors	tumor	B-NP	NNS	O	21	PMOD	-1
23	.	.	O	.	O	13	P	-1

1	In	In	B-PP	IN	O	8	VMOD	-1
2	the	the	B-NP	DT	O	5	NMOD	-1
3	orthotopic	orthotopic	I-NP	JJ	O	5	NMOD	-1
4	xenograft	xenograft	I-NP	NN	O	5	NMOD	-1
5	model	model	I-NP	NN	O	1	PMOD	-1
6	,	,	O	,	O	8	P	-1
7	rAAV2/5-VAS	rAAV2/5-VAS	B-NP	NN	O	8	SUB	-1
8	suppressed	suppress	B-VP	VBD	O	0	ROOT	18	suppressed
9	metastasis	metastasis	B-NP	NN	O	19	NMOD	14	metastasis
10	of	of	B-PP	IN	O	9	NMOD	-1
11	A549	A549	B-NP	NN	O	12	NMOD	-1
12	tumors	tumor	I-NP	NNS	O	10	PMOD	-1
13	to	to	B-PP	TO	O	9	NMOD	-1
14	mediastinal	mediastinal	B-NP	JJ	O	16	NMOD	-1
15	lymph	lymph	I-NP	NN	O	16	NMOD	-1
16	nodes	node	I-NP	NNS	O	13	PMOD	-1
17	and	and	O	CC	O	19	NMOD	-1
18	contralateral	contralateral	B-NP	JJ	O	19	NMOD	-1
19	lung	lung	I-NP	NN	O	8	OBJ	-1
20	.	.	O	.	O	8	P	-1

1	Furthermore	Furthermore	B-ADVP	RB	O	19	VMOD	-1
2	,	,	O	,	O	19	P	-1
3	treatment	treatment	B-NP	NN	O	19	SUB	19	treatment
4	of	of	B-PP	IN	O	3	NMOD	-1
5	immunocompetent	immunocompetent	B-NP	JJ	O	6	NMOD	-1
6	mice	mouse	I-NP	NNS	O	4	PMOD	-1
7	in	in	B-PP	IN	O	3	NMOD	-1
8	the	the	B-NP	DT	O	12	NMOD	-1
9	spontaneous	spontaneous	I-NP	JJ	O	12	NMOD	-1
10	lung	lung	I-NP	NN	O	12	NMOD	-1
11	metastases	metastasis	I-NP	NNS	O	12	NMOD	0
12	model	model	I-NP	NN	O	7	PMOD	-1
13	with	with	B-PP	IN	O	12	NMOD	-1
14	rAAV2/5-VAS	rAAV2/5-VAS	B-NP	NN	O	13	PMOD	-1
15	after	after	B-PP	IN	O	14	NMOD	-1
16	primary	primary	B-NP	JJ	O	18	NMOD	-1
17	tumor	tumor	I-NP	NN	O	18	NMOD	-1
18	excision	excision	I-NP	NN	O	15	PMOD	19	excision
19	prolonged	prolong	B-VP	VBD	O	0	ROOT	0
20	their	their	B-NP	PRP$	O	22	NMOD	-1
21	median	median	I-NP	JJ	O	22	NMOD	-1
22	survival	survival	I-NP	NN	O	19	OBJ	0
23	from	from	B-PP	IN	O	19	VMOD	-1
24	21	21	B-NP	CD	O	23	PMOD	-1
25	to	to	I-NP	TO	O	23	PMOD	-1
26	51.5	51.5	I-NP	CD	O	27	NMOD	-1
27	days	day	I-NP	NNS	O	25	PMOD	-1
28	.	.	O	.	O	19	P	-1

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	Our	Our	B-NP	PRP$	O	4	NMOD	-1
4	results	result	I-NP	NNS	O	5	SUB	0
5	show	show	B-VP	VBP	O	1	NMOD	-1
6	the	the	B-NP	DT	O	7	NMOD	-1
7	effectiveness	effectiveness	I-NP	NN	O	5	OBJ	18	effectiveness
8	of	of	B-PP	IN	O	7	NMOD	-1
9	rAAV2/5-VAS	rAAV2/5-VAS	B-NP	NN	O	8	PMOD	-1
10	as	as	B-PP	IN	O	5	VMOD	-1
11	an	an	B-NP	DT	O	13	NMOD	-1
12	angiogenesis	angiogenesis	I-NP	NN	O	13	NMOD	3	angiogenesis
13	inhibitor	inhibitor	I-NP	NN	O	10	PMOD	0
14	in	in	B-PP	IN	O	5	VMOD	-1
15	suppressing	suppress	B-VP	VBG	O	14	PMOD	18	suppressing
16	tumor	tumor	B-NP	NN	O	17	NMOD	-1
17	growth	growth	I-NP	NN	O	15	OBJ	4	growth
18	during	during	B-PP	IN	O	15	VMOD	-1
19	different	different	B-NP	JJ	O	20	NMOD	-1
20	stages	stage	I-NP	NNS	O	18	PMOD	-1
21	of	of	B-PP	IN	O	20	NMOD	-1
22	tumor	tumor	B-NP	NN	O	23	NMOD	-1
23	progression	progression	I-NP	NN	O	21	PMOD	2	progression
24	,	,	O	,	O	5	P	-1
25	validating	validate	B-VP	VBG	O	5	VMOD	-1
26	the	the	B-NP	DT	O	27	NMOD	-1
27	application	application	I-NP	NN	O	25	OBJ	0
28	of	of	B-PP	IN	O	27	NMOD	-1
29	rAAV2/5-VAS	rAAV2/5-VAS	B-NP	NN	B-DNA	31	NMOD	-1
30	gene	gene	I-NP	NN	I-DNA	31	NMOD	-1
31	therapy	therapy	I-NP	NN	O	28	PMOD	0
32	in	in	B-PP	IN	O	25	VMOD	-1
33	treatment	treatment	B-NP	NN	O	32	PMOD	0
34	against	against	B-PP	IN	O	33	NMOD	18	against
35	lung	lung	B-NP	NN	O	36	NMOD	-1
36	cancer	cancer	I-NP	NN	O	34	PMOD	-1
37	.	.	O	.	O	1	P	-1

